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ABSTRACT
Insulin-like growth factor-1 (IGF-1) plays a central role in cellular growth, differentiation, survival, and cell cycle progression. It is
expressed early during development and its effects are mediated through binding to a tyrosine kinase receptor, the insulin-like growth
factor-1 receptor (IGF-1R). In the circulation, the IGFs bind to IGF-binding proteins (IGFBPs), which determine their bioavailability and
regulate the interaction between the IGFs and IGF-1R. Studies in animal models and in humans have established critical roles for IGFs in
skeletalgrowthanddevelopment.InthisreviewwepresentnewandoldfindingsfrommousemodelsoftheIGFsystemanddiscusstheir
clinical relevance to normal and pathological skeletal physiology.  2010 American Society for Bone and Mineral Research.
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Introduction
F
rom sulfation factor, discovered in the 1950s, to somatomedin
inthe1970s,toinsulin-likegrowthfactor1(IGF-1)inthe1980s,
we have learned that IGFs play a central role in growth,
development, and metabolism. While originally IGFs were
discovered in serum and found to be produced by the liver,
numerous studies in the 1980s demonstrated that virtually all
tissues express IGF-1. The recognition of IGF-1 as an endocrine
(serum) and an autocrine/paracrine (tissue) hormone has helped
the scientific community develop an understanding of how
these two systems function coordinately. It has become clear
that liver IGF-1 is regulated largely by the ambient levels of
growth hormone (GH) secreted from the pituitary, but this is not
necessarily the case for non–hepatic tissue production of IGF-1.
Additionally,theintimaterelationship betweenGHandIGF-1has
made it difficult to attribute discrete actions to each hormone,
andinthepasttwodecades,agreatdealofefforthasbeenmade
to unravel these functions. In this article we discuss the effects of
GH/IGF-1 on the skeleton as derived from mouse models. The
models are presented in the context of what they tell us about
IGF-1’s role as a global growth factor, an endocrine factor, and
a tissue growth factor and are placed, where possible, in the
context of human IGF-1 deficiencies.
IGF as a Global Growth Factor
Given that the bulk of circulating IGF-1 is produced through GH
actionontheliver,itwasexpectedthatinhibitionofGHsignaling
in mice would retard growth significantly. Indeed, in Snell dwarf
(dw/dw) mice, deletion of the transcription factor gene pit1
resulted in a loss of GH production
(1) and reduced bone length
owing to a reduction in cartilage hypertrophy and delayed
epiphyseal ossification.
(2–3) Such alterations are likely the
mechanism behind marked growth retardation at 2 weeks of
age and complete growth arrest at the onset of puberty (4 weeks
of age).
(4) Similar phenotypes were found in the Ames dwarf
mouse(dt/dt),wheredf(prop-1,anupstream regulatorofpit-1)is
absent and GH is again not produced. Further, Ames dwarf male
and female mice had decreases in body weight that were
accompanied by reductions in lean mass, bone area, and bone
mineral content (BMC).
(5) It should be noted, however, that
deficiencies in prolactin and thyroid-stimulating hormone (TSH)
are also present in both Snell
(6,7) and Ames
(8) dwarf mice. Thus
the aforementioned phenotypic changes may not be due
entirely to GH effects. When Stat5b, a downstream effector of the
GH receptor (GHR), was ablated in mice, body weights and bone
lengths were reduced in a manner similar to Ames and Snell
dwarf mice, although this effect was mainly apparent in male
mice.
(9) The defects of Snell and Ames dwarf as well as Stat5b
 / 
mice resulted in blunted GHR activity and are similar to the
clinical characteristics of Laron syndrome in humans, where the
GHR is mutated. The clinical details of Laron syndrome are
extensive and beyond the scope of this review, but they have
been published previously.
(10) These patients have low spinal
and femoral neck areal bone mineral density (BMD) but
volumetric BMD is normal. Bone size is markedly decreased
compared with controls.
(11) It should be noted that the Stat5b
 / 
model has clinical significance of its own given that Stat5b
mutations have been found in humans, and the phenotype of
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2543growth retardation is similar to that of Stat5b
 /  mice. However,
the Stat5b
 /  mouse model has a sexually dimorphic phenotype
(growth retardation is largely in males), whereas human cases
of Stat5b deletions/mutations have demonstrated significant
(and comparable) growth retardation in both females
(12–14) and
males.
(15)
Total inactivation of the Igf1 gene in mice resulted in 80%
perinatal lethality. The surviving pups were 50% smaller than
controls, highlighting the importance of Igf-1 in early growth.
(16)
This has been confirmed in studies of embryonic growth
showing that fetal mice had short-limb dwarfism delays in
mineralization and increased chrondrocyte apoptosis.
(17) In
Igf1
 /þ mice it was reported that body weights, femur lengths,
and BMD values were reduced in females and males, but the
differences in males appeared only after puberty.
(18) In terms of
bone morphology, Igf1
 /þ mice were found to have significantly
reduced cortical area and periosteal circumference by 2 months
(after puberty) in both males and females. This finding is
supported by another study of Igf1
 /þ mice that indicated that,
at least in terms of transverse size (periosteal circumference), the
differences appear as early as 3 weeks of age.
(19) Bikle and
colleagues reported that Igf1
 /  mice had a 24% reduction in
cortical bone size and shortened femoral lengths, but trabecular
bone density and connectivity were increased.
(20) These
investigators also demonstrated a defect in osteoclastogenesis
and showed that osteoclasts were smaller with fewer nuclei in
these knockouts. Additionally, expressions of RANKL and c-fms
[the receptor for monocyte colony-stimulating factor (M-CSF)]
were reduced significantly.
(21) Interestingly, human patients with
IGF1 gene deletions have been identified. Patients homozygous
for IGF1 gene deletions exhibit growth retardation (short stature)
and normal genitalia and proceed through puberty, but at a
much slower rate.
(22) Bone size is reduced at birth, and vertebral
BMD was reduced, but this was due primarily to a decrease in
bone volume.
(23) IGF-1 replacement therapy had a significantly
greater effect on bone volume than on bone density. Mice with
deletionoftheIgf1receptor(Igf1r
 / )resembled Igf1nullmicein
that pups were born smaller than controls (organ hypoplasia)
anddiedshortlyafterbirth.
(24)Inaddition,the authorsnotedthat
primary ossification centers in the cranial and facial bones
appeared later in Igf1r
 /  mice compared with controls. Studies
of Igf1r
þ/  mice found significant reductions in body weight by
4 weeks of age, although this was noticed only in males.
(25)
Although human patients with total IGF1R deletions have not
been identified, patients with heterozygous mutations in the
IGF1R receptor have been identified
(26–29) and show various
forms of intrauterine growth retardation and blunted postnatal
growth,
(30–34) as might be expected from studies of Igf1r
 / 
mice. When the downstream effector of Igf1r, the insulin-
receptor substrate 1 (Irs-1) was mutated in mice, significant
reductionsinbodyweightwereapparentfrombirthandthrough
adulthood.
(35) Interestingly, these Irs1
 /  mice showed no delay
in ossification of their long bones. In contrast, analysis of mice
that had a spontaneous mutation in Irs1 resulting in failure to
translate the protein showed growth retardation, low bone
mineral density, reduced cortical and trabecular thickness, and
low bone-formation rates.
(36) The human phenotype is similar to
the latter model in that weight and body length are reduced at
birth.
(37)
Reduced Igf-1 bioavailability was demonstrated in transgenic
mice with ubiquitous expression of Igf-binding proteins (Igfbps)
and the acid-labile subunit (ALS). Overexpression of ALS resulted
in reduced body weight gains during the first 3 weeks of growth
and significantly reduced body weights through puberty.
(38)
Overexpression of Igfbp-1 resulted in growth retardation and a
delay in mineralization of several bones (ie, craniofacial,
metacarpal, and vertebral).
(39) Igfbp-2 overexpression also
resulted in growth retardation and mineralization defects.
Specifically, whole-body BMC, femoral BMC, tibial BMC, and
femoral volume were reduced in Igfbp2 transgenics.
(40) In Igfbp3
transgenics, overexpression demonstrated a similar phenotype
with decreases in body weight, cortical bone density, cortical
bone volume, and cortical thickness.
(41) These deficiencies were
likely a result of a surface-specific cellular deficiency because
bone-formation rates were significantly reduced on the
periosteal surface. Further, cancellous bone density and
trabecular thickness were decreased in Igfbp3 transgenics.
Similar changes in cortical and cancellous bone were found in
Igfbp5 transgenics, although it was reported that the skeletal
phenotype was more severe in males than in females.
(42)
Endosteal bone formation was not inhibited but rather was
enhanced as a result of Igfbp-5 overexpression. It should be
noted that these Igfbp transgenics often do not alter total serum
Igf-1 levels. However, in Igfbp overexpression models, although
serum Igf-1 levels may be normal, the amount of extracellular
fluid Igf-1 that is available to bind to tissue receptors is reduced,
and this likely contributes to the observed bone and growth
phenotypes.
In 1988, Mathews and colleagues created a transgenic mouse
line expressing human IGF-1 in nearly all tissues.
(43) During
puberty (4 to 6 weeks of age), both female and male transgenic
mice exhibited significant increases in body weight that lasted
throughout the study (52 weeks of age). Numerous organ
weights were found to be larger in mice overexpressing human
IGF-1 (owing to hyperplasia), indicating that IGF-1 action from
birth and through puberty leads to proportional size increases in
a variety of tissues. However, this global ‘‘scaling up’’ of body size
did nothold trueforlongitudinal growth ofthe skeletonbecause
the tibias and radii of transgenic mice were identical in length to
those of control mice. Currently, there is no known human
condition that directly mirrors the tissue IGF-1 overexpression
model, although patients with trisomy 15q26, and thus
ubiquitous upregulation of the IGF-1R, also exhibit overgrowth
and tall stature.
(44–45)
The abovementioned studies indicate a common theme of
growth inhibition and, in many cases, impaired skeletal
development in the presence of a global GH/IGF-1 deficiency
(Table 1). However, specific changes in body composition, bone
size/shape, and timing of ossification are highly variable and
appear to depend on sex, genetic background, age, and where
along the GH/IGF-1 signaling pathway the disruption exists. To
more specifically control for these variables, mouse models were
created to tease apart the endocrine (serum) role of Igf-1 from its
autocrine/paracrine (tissue) role.
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Target Mutant name
Genetic
background Skeletal phenotype Ref
Human
counterpart (ref)
Global GH
action
Pit1
 / 
(dw/dw, Snell)
Mixed (from
outbred)
GR, abnormal growth plate,
decreased linear growth.
(2,72) Mutation in Pit1 locus affect
multiple targets. Patients
exhibit short stature
(MIM No. 173110).
Prop1
 / 
(dt/dt, Ames)
Mixed (from
outbred)
GR, reduced bone area and BMC (73,5) Mutation in the Prop1 locus
affect multiple targets.
Patients exhibit short stature
(MIM No. 601538).
Ghrhr
 /  (lit/lit) C57BL6 GR (60% of adult size), reduced
cortical BMD, normal trabecular
bone.
(74) Isolated GHD type 1B
(MIM No. 139191)
Ghrbp
 /  C57BL6 GR (60% of adult size) reduced
tibial length and decreased
hight of growth plate
(75–76) Laron syndrome
(MIM No. 262500)
Stat5b
 /
  129 x BALB/c
outcross
GR, impaired longitudinal
growth, impaired endochondral
ossification
(9,77) GH insensitivity with
immune deficiency
(Stat5b gene
deletion) (MIM No. 604260)
GH antagonist
triglyceride
C57BL/6J SJL/
J
GR (60% of adult size), fourfold
increased body adiposity,
reduced BMD
(78) and
  Not applicable
GH triglyceride C57BL/6J GH overexpression increased
body weight, tibial mass, and
tibial density
(79) Acromegaly (MIM No.
102200)/
gigantism, Sotos syndrome
(MIM No. 117550)
Global IGF-1
action
Igf1
 /  CD-1 GR (30% of adult size), reduced
cortical BMD, increased
trabecular BMD
(16,80) Igf1 mutation(26,81)
C57BL6 Igf1 gene deletion(22)
75% NMRI
genetic
background
(MIM No. 608747)
Igf1
m/m (MIDI) Not specified GR, reduced femoral length and
areal BMD
(82) Not applicable
Igf1
þ/ 
(haploinsufficiency)
CD1 GR (70% of adult size), reduced
femoral length and areal BMD
(18,19) Not described in the
literature
MF1/DBA
Igf1TG (ubiquitous
expression)
Not specified Increased body weight and
organ growth, normal skeletal
size and morphology
(43) Not applicable
Igf1r
 /
  129/Sv Intrauterine GR, lethal (neonates
at 45% of WT) delayed bone
ossification
(24) Not described in the
literature
Igf1rþ/
 
(haploinsufficiency)
129/Sv GR (90% of adult size) (25) IGF-1 resistance
(MIM No. 147370)
Inbred mouse lines C3H Serum and skeletal Igf-1 levels
were greater in C3H mice which
have a significantly larger
femoral total area and cortical
area as compared to C57BL/6
mice
(83) Not applicable
C57BL/6
Global IGF-2
action
IGF2
 /  MF1 C57BL/6
Chimera
GR (60% of neonate size) (84) Not described in the
literature
Igf2TG 75% NMRI
genetic
background
Increased body weight, no
effect on femoral architecture
or BMD.
(80) Not applicable
(Continued)
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Target Mutant name
Genetic
background Skeletal phenotype Ref
Human
counterpart (ref)
Global IGF axis Igf1
 /  Igf2
þ/ 
(haploinsufficiency)
MF1 C57BL/6
Chimera
GR (30% of adult size) (24) Not described in the
literature
Igf1
 /  Igf1r
 /  Lethal (neonates at 45% of WT) (24) Not described in the
literature
Igf2
þ/  Igf1r
þ/ 
(haploinsufficiency)
GR (30% of adult size) (4) Not described in the
literature
Igf1
 /  GHR
 /  Mixed Breeding
(C57BL/6,
129Sv, MF!/
DBA)
GR (17% of adult size) (85) Not described in the
literature
Global IGF-1R
mediators
Irs1
 /  CD-1 C57BL/6
Chimera
Growth retardation (50% of
adult size); no delay in long
bone ossification
(35) Not described in the
literature. Heterozygous
mutation is associated with
metabolic disorder.(86)
Irs1 sml/sml C3.SW-H2b/SnJ Growth retardation (50% of
adult size), low bone mineral
density, reduced cortical and
trabecular thickness, and low
bone-formation rates
(36)
Akt1/2 MF1 C57BL/6
Chimera
Intrauterine GR, lethal (neonates
at 45% of WT), delayed bone
ossification
(87) Not described in the
literature
Foxo1/3/4 (conditional
global deletion)
FVB/N C57BL6
mixed
Reduced BMD, significant
reductions in trabecular bone
(88) Not described in the
literature
Global IGF
bioavailability
Igfbp1TG C57BL/6/CBA GR, reduced skeletal
mineralization
(39) Not applicable
Igfbp2
 /  C57BL6 Sex-related decrease in BMD
(male)
(89) Not described in the
literature
Igfbp2 TG Not specified Decreased (10%) carcass
weight, reduced bone length,
bone cross-sectional area, and
BMC
(40,90) Not applicable
Igfbp3
 /  C57BL6 No effects on body weight or
linear growth were noted
(91) Not described in the
literature
Igfbp3 TG CD-1 Reduced volumetric and cortical
BMD, increased resorption
(41) Not applicable
Igfbp4
 /  C57BL/6 GR (85% of adult size) (91) Not described in the
literature
Igfbp4 TG FVB/N GR (92) Not applicable
Igfbp5
 /  C57BL/6 No effects on body weight or
linear growth were noted
(91)
Igfbp5 TG C57BL/6JxCBA/
CA
Sex-related decrease in BMD,
impaired mineralization,
decreased BFR
(42) Not applicable
ALS
 /  CD-1 GR (80% of adult size), reduced
volumetric and cortical BMD,
10% reduction in femoral length
(93) IGFALS deficiency (ALS gene
deletion)
C57BL/6 (MIM No. 601489)
ALS TG Balb C Modest GR
CD-1 (38) Not applicable
PappA
 / 
(IGFBP-4 protease)
C57BL/6 129Sv GR (60% of adult size) (94) Not described in the
literature
PappATG C57BL/6J XCBA/
CA
Increased body weight (95) Not applicable
Igfbp3
 /– -4
 /  -5
 /  C57BL/6 GR (80% of adult size) (91)
Igfbp4
 /  ; PappA
 /  129/C57BL/6 GR (90% of adult size) (94)
(Continued)
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Studies from inbred mouse strains with distant genetic back-
groundsthat havemarkedly differentserum Igf-1concentrations
have reinforced the importance of serum Igf-1 for bone
development.
(46) The mouse strains with low Igf-1 (C57BL/6J)
have reduced total BMD and cortical thickness, whereas mice
with higher serum Igf-1 levels (C3H/HeJ) show increased total
BMD and femoral cortical thickness. In addition, congenic mice
(B6.C3H.6T)witha40%reductioninserumIgf-1alsohadreduced
BMD and delayed development.
(47) Given that the liver is
responsible for nearly 75% of serum Igf-1 levels, ablation of Igf1
gene expression in the liver was a promising approach to
quantify the effects of serum Igf-1 on skeletal growth and
development. Liver-specific Igf-1-deficient (LID) mice were
created using the Cre-LoxP system. Preliminary data indicated
an80%decrease inserumIgf-1levels,nochangeinbody weight,
and a small but significant decrease in body length from 3 to
8weeksofage.
(48)Asubsequent study examinedskeletal growth
of LID mice in detail from 4 to 52 weeks of age and confirmed
theseinitialfindingswhilepresentingnewdata onthe roleofIgf-
1 in skeletal development after puberty.
(49) Results of this study
indicated that a constitutive loss (from birth) of serum Igf-1
resulted in significant reductions in body weight after puberty.
Although no alterations in trabecular bone were found,
significant decreases in femoral total area (Tt.Ar), cortical area
(Ct.Ar), and polar moment of inertia (Jo) were found beginning at
8 weeks of age. As a result, femurs were more slender (less
robust) with reduced stiffness and reduced strength in bending.
Thus reductions in serum Igf-1 tended to target cortical bone by
Table 1. (Continued)
Target Mutant name
Genetic
background Skeletal phenotype Ref
Human
counterpart (ref)
Endocrine
IGF-1
Liver-specific Igf-1 TG
(Hit)
C57BL/6 Increased body weight and
linear growth; increased all
skeletal traits including tissue
mineral density
(52–53,96–97)
FVB/N
Liver-specific IGF1
 / 
(LID)
FVB/N Normal growth, reduced
volumetric and cortical BMD,
5% reduction in femoral length
(93)
C57BL/6
LID ALS
 /  FVB/N C57BL6
mixed
GR (70% of adult size), reduced
cortical and trabecular BMD
Autocrine/
paracrine
IGF-1 activity
or bioavailbility
Osteoblast-specific
Igf1 TG
FVB/N Increased volumetric and
cortical BMD
(64)
Osteoblast-specific
Igfbp4 TG
FVB/N Decreased in bone volume and
cortical BMD
(61)
Osteoblast-specific
IGF1R
 / 
C57BL/6 x FVB/
N
Normal growth, impaired
mineralization
(58)
Osteoblast-specific
PappA TG
C57BL/6J XCBA/
CA
Increased calvarial BMD and
tibial/femoral bone area and
periosteal circumference
(98)
Chondrocyte-specific
IGF1
 / 
C57BL/6 X SJL Body length, areal BMD, and
BMC were reduced between
4 and 12 weeks
(56)
Skeletal muscle/
bone-specific IGF1
 / 
(collagen 1 and 2
expressing cells)
C567BL/6 X
FVB/N
Reduced body weight, femoral
BMD, femoral bone size, mineral
apposition rate, and bone-for-
mation rate.
(57)
IGF1
 /  liver-specific
Igf2 TG
75% NMRI
genetic back-
ground
GR, adults show similar body
weight andlength totheIgf1
 / 
mice.
(80)
Endocrine and
autocrine/
paracrine IGF-1
interplay
Igf1
 /  liver-specific
Igf1 TG (KO-HIT)
FVB/N Normalized skeletal growth and
development due to threefold
increase in endocrine (serum)
Igf-1 levels.
(52–53)
Igf1
 /  liver-specific
Igf1 KI
C57BL/6 CBA Physiologic levels of
liver-derived IGF-1 restored
body size of the Igf1 null mice
to  70% of WT size
(65)
 S Yakar personal note.
Mendelian Inheritance in Man¼MIM; www.ncbi.nlm.nih.gov/omim/).
IGF-1 AND BONE Journal of Bone and Mineral Research 2547preventing periosteal apposition during growth. Interestingly,
marrow area (Ma.Ar) was not altered during early growth and
actuallydecreasedrelativetocontrolsfrom16to32weeksofage
(endosteal infilling), suggesting that when serum Igf-1 levels are
lowered early during growth, bones become more slender,
but skeletal elements are able to activate a compensatory
adaptive response by adding more bone endosteally to support
increases in body weight. This was evident by an increase in
relative cortical area (RCA) during growth (Fig. 1) such that the
total amount of bone tissue present per total area of bone
increased owing to endosteal infilling.
SerumIgf-1levelsalsohavebeenreducedinmousemodelsby
altering the expression of one or more Igf-1-binding proteins. In
Igfbp3 knockout mice, serum Igf-1 levels were reduced by 40%,
but body weight and length were increased by 8 weeks
compared with controls.
(48) Interestingly, these mice had
decreased femoral trabecular bone volume fraction (BV/TV)
and trabecular number (Tb.N) with no apparent changes in
cortical bone size or tissue amount, suggesting that Igfbp3 may
have an Igf-1-dependent or -independent effects on the
skeleton. The ALS is an important binding protein of Igf-1 and
Igfbp-3 in serum, and when it is ablated in mice (ALS KO), it
results in 65% reductions in serum Igf-1 levels, similar to the LID
model. A detailed skeletal analysis of ALS KO mice from 4 to
16 weeks indicated reductions in body weight and body length
throughout growth inbothfemaleandmalemice.
(50) Inaddition,
by adulthood (16 weeks), ALS KO mice, both females and males,
had reduced Tt.Ar., Ct.Ar., Ma.Ar, Jo, and robustness (more
slender). Similar to LID mice, ALS KO mice are also able to
compensate for smaller, more slender bones through marrow
infilling[reducingMa.Arandincreasingtheirrelativecorticalarea
(RCA)]. Interestingly, the increased slenderness and compensa-
tory increased marrow infilling (increased RCA) were more
prominent in female than male ALS KO mice (Fig. 1). The data
from male LID and ALS KO mice indicate a common role for
serum Igf-1 in maintaining periosteal apposition during growth.
The ALS KO mouse model is now of particular interest because
human patients with ALS deficiency have been and continue to
be reported in the literature. Although detailed quantification of
skeletal structures in ALS-deficient patients has not been
performed, a review of case reports has been published that
indicates short stature and reduced BMD in a number of
patients.
(51)
Increased Igf-1 levels in serum were demonstrated in mice
expressing hepatocyte-specific rat Igf1 transgene (HIT). HIT mice
exhibit two- to threefold increases in serum Igf-1 levels, which
were accompanied by increases in body weight, body length,
femoral length, and femoral Tt.Ar, Ct.Ar, Ct.Th, Jo, and
robustness.
(52–53) Trabecular architecture also was examined in
the HIT model, but only a few changes were observed at
16 weeks of age (Tb.Th increased in HIT mice). Thus the HIT
phenotype is a scaling up of body size and cortical skeletal size
with proportional changes in lean and fat mass. It should be
noted that the HIT model is one of the few examples where Igf-1
alteration changed the composition of bone; HIT mice at
16 weeks were found to have a higher tissue mineral density
(TMD) in both cortical and cancellous bone, indicating that more
mineral was present in a given volume of bone than in control
mice.
Together, studies of mice with reductions in serum Igf-1
revealed minor changes in body weight and length but
significant decreases in transverse bone growth (Table 1).
Reductions in serum Igf-1 during postnatal growth are extremely
important in establishing bone robustness and suggest a
possible role in determining increased fracture risk during
adulthood and aging. On the other hand, increases in serum
Igf-1 levels during growth lead to enhancement of all bone
traits and may play a protective role later on during aging.
They also emphasize the importance of serum Igf-1 in
contributing to cortical size and bone density. Indeed, several
papers have reported skeletal abnormalities in humans with
low serum IGF-1.
(54,55) In general, these have been patients
with severe GH deficiency. These patients usually have normal
volumetric BMD values and smaller bones. Increased fractures
have been reported in some studies.
(55) These studies are
difficult to relate to the mouse models because, except for the
case of Igf1 gene deletion,
(23) GH deficiency also has been
present.
Fig. 1. (A) Relative cortical area (RCA¼Ct.Ar./Tt.Ar.) versus body weight for male LID and control mice during growth, as published previously.
(49)
(B) RCA versus body weight for male ALS KO and control mice during growth, as published previously.
(50) For both LID and ALS KO mice, RCA is
increased as body weight increases during growth compared with control mice, illustrating a small compensatory response of bone to decreased
periosteal apposition.
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Tissue-specific regulation of IGF-1 is an important feature of
many developmental processes. In the past 10 years, we have
advanced our understanding of IGF-1 action on bone using cell-
type specific IGF-1/IGF-1R inactivation. In a model where
chondrocyte Igf-1 synthesis was disrupted, significant reductions
in body weight, body length, total-body BMD, and femoral
length were observed beginning at 4 weeks of age in both
femaleandmalemice.
(56)Further,femoralwidth,asmeasuredby
periosteal circumference, was reduced in both sexes, although
the differences were greater for males than for females.
Conditional deletion of Igf-1 in skeletal muscle and bone
resulted in decreased femoral size, increased apoptosis, and
decreased bone-formation rate.
(57)
When the Igf-1R was disrupted in osteoblasts (DIgfr mice), no
alterations in body size, weight, or femoral length by 6 weeks of
age were found. However, DIgfr mice showed significant
reductions in distal metaphyseal trabecular BV/TV, Tb.Th, TB.N,
and MAR as well as increased osteoid volume and osteoid
surface.
(58) This study was crucial to establishing the role of Igf-1
in bone mineralization. Mice bearing Igf1i or Igf1r gene deletions
also have been useful for determining if the known anabolic
factors for bone require expression of Igf-1. Mice with an Igf1r
depletion in osteoblasts showed decreased endosteal bone
formation in response to PTH compared with controls. This
defect was demonstrated in bone marrow stromal cells derived
from these animals through a decreased number of alkaline
phosphatase colonies and decreased mineralization in response
to PTH.
(59) These findings also have been replicated in Igf1
knockout mice.
(60) It should be noted that tissue-specific effects
of Igf-1 have been hard to quantify because they are not easily
separable from the endocrine reservoir of Igf-1. Thus, in the
previous example of DIgfr mice, disruption of the Igf-1r will
impair both autocrine/paracrine and endocrine Igf-1 effects on
osteoblasts.
Tissue-specific expression of Igfbps leads to decreased Igf-1
bioavailability and generally shows phenotypes similar to the
global Igfbp transgenics, namely, reduced body weight and
length. Igfbp-4 overexpression in osteoblasts resulted in
decreased femoral cortical density, cortical thickess, and
periosteal circumference in both males and females by 6 weeks
of age.
(61) Mice expressing Igfbp-5 under the osteocalcin
promoter demonstrated decreased BMD, trabecular bone
volume, and bone formation,
(62) as well as mineralization defects
indicated by reduced mineral/matrix ratio in cortical bone and
reduced collagen maturity in secondary ossification centers.
(63)
As was stated previously, local expression of Igfbps does not
distinguish between autocrine/paracrine and endocrine Igf-1
effects but rather blocks the Igf-1 axis in a cell-specific manner. In
contrast, Igf-1 overexpression in osteoblasts under the osteo-
calcin promoter (OC-Igf1 transgenic mice) resulted in no change
in serum Igf-1 levels or body weights up to 16 weeks but
significant increases in cortical and trabecular BMD as well as
trabecularbonevolumeandtrabecularthickness.
(64)IntheseOC-
Igf1 mice, histomorphometric parameters were no different from
those of control mice at the later age (24 weeks), but increases in
bone-formation rate were apparent at 6 weeks of age, indicating
that increased bone accrual is accomplished largely during
puberty.
As a point of comparison with the previously discussed HIT
mouse mode, the KO-HIT mouse model lacks tissue Igf-1 in all
tissues, and the sole source of Igf-1 production is through a
transgene expressed in the liver. Thus serum Igf-1 levels are
identical to HIT mice and threefold higher than control mice.
Differences between HIT and KO-HIT mice therefore represent
the consequences of tissue Igf1 gene ablation from birth.
Interestingly, body weight and length were not increased in KO-
HIT mice, as they were in HIT mice, and morphologic analyses
revealed that KO-HIT mice had skeletal properties similar to
controls starting at 8 weeks of age.
(52) However, early in
development (before 8 weeks), significant reductions in femoral
length, Tt.Ar, Ct.Ar, and robustness were evident. By 16 weeks,
KO-HIT traits were normalized to control levels (eg, femoral
length, Tt.Ar., and robustness) or exceeded control levels in a
manner similar to HIT mice (ie, Ct.Ar). These findings are in
agreement with another study in which liver Igf-1 was
reexpressed in Igf1 null mice resulting in a partial postnatal
restoration of serum Igf-1 levels ( 50% of normal) and body
weight ( 70% of normal).
(65) Thus tissue Igf-1 appears crucial for
early postnatal and pubertal development of cortical bone, but
serum Igf-1 can permit ‘‘catchup’’ growth postpubertally
(Table 1). Whether reexpression of normal levels of serum Igf-
1 sufficient for normal growth in the absence of tissue Igf-1
remains unknown.
Final Considerations
Throughout this article, the skeletal phenotypes of Igf-1 mouse
models have been presented without context of their genetic
backgrounds. This is an important consideration, and for each
model discussed in this article, genetic backgrounds are given
(where available) in Table 1. In addition, Table 1 offers a more
extensive list of mouse models relating to the GH/Igf-1 axis as
well as summaries of their skeletal phenotypes. Numerous
studies indicate that differences in genetic background, whether
complete
(66,67) or even partial,
(68–71) can result in significant
alterations in skeletal properties and mechanical function.
Therefore, any assessment of genetically engineered mice must
consider the possibility that gene interactions from genetic
background effects may determine at least partially the
phenotype. As indicated in Table 1, the majority of Igf-1 mouse
modelshave beencreated onafewselectbackgrounds (ie,CD-1,
C57BL/6, and FVB/N) or on mixed backgrounds. Nevertheless, a
review of the existing data from the different genetic back-
grounds used indicates that the major roles of Igf-1 (eg, growth
retardation from global deficiency, periosteal inhibition from
reduced serum Igf-1 levels, etc.) exist despite differences in
genetic background.
Concluding Remarks
After 60 years of investigation, it is apparent that the GH/IGF axis
plays a prominent regulatory role in skeletal development and
mineral acquisition. Clinical studies as well as animal models
IGF-1 AND BONE Journal of Bone and Mineral Research 2549have taught us that global loss of IGF-1 affects growth and
skeletal gains at all ages, resulting in short stature and slender
and weaker bones. With the development of a tissue-specific
gene approach, we have advanced our knowledge regarding
IGF-1’s mode of action. We now know that loss of serum IGF-1
affects mainly postpubertal bone accrual. Longitudinal studies
have demonstrated the importance of serum IGF-1 in transverse
bone growth and periosteal bone apposition, as well as in bone
adaptation to increases in body weight. We have learned that
loss of tissue IGF-1 affects early postnatal and prepubertal
growth, but there is some compensation when serum IGF-1
levels increase postpubertally. These studies also clearly
demonstrate that the IGF-1 axis in osteoblasts is a strong
determinant of bone mineralization.
Future Directions
Notwithstanding our extensive knowledge of IGF-I action on the
growing skeleton, its role in skeletal homeostasis during aging is
still unclear. Moreover, our understanding of IGF-1 interactions
with steroid hormones, insulin, PTH, sclerostin, and the Wnt
pathway and their effects on the skeleton during growth and
aging is incomplete. Other open questions regarding IGF-1
action include its role in osteocyte function and in osteoclas-
togenesis. Lastly, perhaps the most important question is: How
and when should we intervene through manipulation of the GH/
IGF axis to obtain a more robust, mechanically fit skeleton.
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